1825 related articles for article (PubMed ID: 31474630)
1. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
Kim SK; Kim KI; Kim SR
Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630
[TBL] [Abstract][Full Text] [Related]
2. [An Overview of NAFLD/NASH in Japan].
Kim SR; Kim KI
Yakugaku Zasshi; 2016; 136(4):565-72. PubMed ID: 27040340
[TBL] [Abstract][Full Text] [Related]
3. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
Perumpail RB; Wong RJ; Ahmed A; Harrison SA
Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
[TBL] [Abstract][Full Text] [Related]
5. Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments.
Roeb E; Geier A
Z Gastroenterol; 2019 Apr; 57(4):508-517. PubMed ID: 30965381
[TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic Steatohepatitis: A Review.
Sheka AC; Adeyi O; Thompson J; Hameed B; Crawford PA; Ikramuddin S
JAMA; 2020 Mar; 323(12):1175-1183. PubMed ID: 32207804
[TBL] [Abstract][Full Text] [Related]
7. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
8. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Watanabe S; Hashimoto E; Ikejima K; Uto H; Ono M; Sumida Y; Seike M; Takei Y; Takehara T; Tokushige K; Nakajima A; Yoneda M; Saibara T; Shiota G; Sakaida I; Nakamuta M; Mizuta T; Tsubouchi H; Sugano K; Shimosegawa T; ;
J Gastroenterol; 2015 Apr; 50(4):364-77. PubMed ID: 25708290
[TBL] [Abstract][Full Text] [Related]
9. Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study.
Barritt AS; Gitlin N; Klein S; Lok AS; Loomba R; Malahias L; Powell M; Vos MB; Weiss LM; Cusi K; Neuschwander-Tetri BA; Sanyal A
Contemp Clin Trials; 2017 Oct; 61():33-38. PubMed ID: 28735109
[TBL] [Abstract][Full Text] [Related]
10. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
[TBL] [Abstract][Full Text] [Related]
11. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
[TBL] [Abstract][Full Text] [Related]
12. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
Dhamija E; Paul SB; Kedia S
Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
[TBL] [Abstract][Full Text] [Related]
13. [An interpretation of the AASLD practice guideline on the diagnosis and management of nonalcoholic fatty liver disease in 2017].
Nan YM; Fu N; Li WC; Kong LL; Yuan XW; Zhang SY; Liu LD; Lu Y; Cui LY
Zhonghua Gan Zang Bing Za Zhi; 2017 Sep; 25(9):687-694. PubMed ID: 29108191
[TBL] [Abstract][Full Text] [Related]
14. Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
Golabi P; Bush H; Younossi ZM
Clin Liver Dis; 2017 Nov; 21(4):739-753. PubMed ID: 28987260
[TBL] [Abstract][Full Text] [Related]
15. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020.
Tokushige K; Ikejima K; Ono M; Eguchi Y; Kamada Y; Itoh Y; Akuta N; Yoneda M; Iwasa M; Yoneda M; Otsuka M; Tamaki N; Kogiso T; Miwa H; Chayama K; Enomoto N; Shimosegawa T; Takehara T; Koike K
J Gastroenterol; 2021 Nov; 56(11):951-963. PubMed ID: 34533632
[TBL] [Abstract][Full Text] [Related]
16. Nonalcoholic Fatty Liver Disease--The Clinician's Perspective.
Agrawal S; Duseja A
Trop Gastroenterol; 2014; 35(4):212-21. PubMed ID: 26349165
[TBL] [Abstract][Full Text] [Related]
17. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
[TBL] [Abstract][Full Text] [Related]
18. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
Zhou JH; Cai JJ; She ZG; Li HL
World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
[TBL] [Abstract][Full Text] [Related]
19. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies.
Oda K; Uto H; Mawatari S; Ido A
Clin J Gastroenterol; 2015 Feb; 8(1):1-9. PubMed ID: 25575848
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease.
Satapathy SK; Sanyal AJ
Semin Liver Dis; 2015 Aug; 35(3):221-35. PubMed ID: 26378640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
